PROTONIX IV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROTONIX IV (PROTONIX IV).
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
| Metabolism | Extensively metabolized in the liver via CYP2C19 and CYP3A4 isoenzymes. |
| Excretion | Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces. |
| Half-life | 1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment. |
| Protein binding | 96-98% bound to albumin. |
| Volume of Distribution | Approximately 0.15-0.3 L/kg; indicates distribution primarily in extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 77% (not applicable to IV formulation; IV has 100% bioavailability). |
| Onset of Action | Intravenous: Onset of acid suppression occurs within 30-60 minutes; maximal effect by 1-2 hours. |
| Duration of Action | Acid suppression persists for up to 24 hours following a single IV dose; duration is dose-dependent. |
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
| Dosage form | INJECTABLE |
| Renal impairment | No dosage adjustment necessary for renal impairment; use caution in severe renal impairment (CrCl <10 mL/min). |
| Liver impairment | For Child-Pugh Class A: 40 mg IV once daily; Class B and C: dose reduction to 20 mg IV once daily is recommended. |
| Pediatric use | 1-16 years: weight-based dosing: 5-10 kg: 5 mg IV once daily; 10-20 kg: 10 mg IV once daily; ≥20 kg: 20 mg IV once daily. Maximum 40 mg IV once daily. |
| Geriatric use | No specific geriatric dose adjustment; monitor renal function and consider lower starting doses due to decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROTONIX IV (PROTONIX IV).
| Breastfeeding | Excreted in human milk; M/P ratio not determined. Potential for adverse effects in infant (gastric acid suppression, GI disturbances). Use caution; consider benefits vs risks. |
| Teratogenic Risk | Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Crosses placenta; risk in first trimester unknown. Use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to pantoprazole or any component of the formulation"]
| Precautions | ["Clostridium difficile-associated diarrhea","Bone fracture risk with long-term use","Hypomagnesemia with prolonged use","Acute interstitial nephritis","Cutaneous lupus erythematosus","Cyanocobalamin deficiency with long-term use","Atrophic gastritis risk with long-term use"] |
Loading safety data…
| No specific monitoring required; standard obstetric care. Assess for adverse maternal effects (e.g., hypomagnesemia with prolonged use). |
| Fertility Effects | No known impairment of fertility based on animal studies. No human data. |